Latest releases

04.09.2020

CR, PR

Herantis Pharma to Host a Webinar on the Cerebral Dopamine Neurotrophic Factor (CDNF) Phase I-II Data Readout
27.08.2020

CR, PR

Herantis Pharma Plc Announces CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months
25.02.2020

CR, FN, GR

Herantis Pharma Plc announces topline results of Phase 1-2 CDNF trial
30.12.2019

CR, FN, GR

Herantis Pharma Plc provides update on non-invasive next generation CDNF (xCDNF) development
19.12.2019

CR, FN

Herantis Pharma Plc completes patient treatments in main study of Phase 1-2 CDNF trial in Parkinson’s disease
26.09.2019

CR, FN

Herantis Pharma Plc Provides Update on Timeline for Ongoing Phase 1-2 CDNF Trial
06.07.2018

CR, FN

Herantis Pharma initiates non-invasive CDNF development program, announces licensing agreement with University of Helsinki
29.03.2018

CR, PR

Herantis Pharma publishes an introductory video on its drug candidate CDNF for the treatment of Parkinson’s disease
14.02.2018

CR, FN

Herantis Pharma opening recruitment in Parkinson’s disease study in Helsinki and Lund based on favorable first CDNF safety assessment
27.09.2017

CR, FN

Herantis Pharma has initiated patient recruitment and consented first patient in CDNF study in Parkinson’s disease

Quick links

Analyst Coverage »

Financial Calendar »

General Meetings »

Financial Information »

Share Information »

Share Monitor »

Investor Relations »

Corporate Governance »